Last reviewed · How we verify
CXL-1020 Dose for Echo Cohort A — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CXL-1020 Dose for Echo Cohort A (CXL-1020 Dose for Echo Cohort A) — Bristol-Myers Squibb.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CXL-1020 Dose for Echo Cohort A TARGET | CXL-1020 Dose for Echo Cohort A | Bristol-Myers Squibb | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CXL-1020 Dose for Echo Cohort A CI watch — RSS
- CXL-1020 Dose for Echo Cohort A CI watch — Atom
- CXL-1020 Dose for Echo Cohort A CI watch — JSON
- CXL-1020 Dose for Echo Cohort A alone — RSS
Cite this brief
Drug Landscape (2026). CXL-1020 Dose for Echo Cohort A — Competitive Intelligence Brief. https://druglandscape.com/ci/cxl-1020-dose-for-echo-cohort-a. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab